vimarsana.com
Home
Live Updates
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated ... : vimarsana.com
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated ... : vimarsana.com
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated ...
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients —
Related Keywords
Hong Kong ,
China ,
United States ,
Poland ,
Shanghai ,
Polish ,
American ,
Atholl Tweedie ,
Zhou Yi ,
Ben Atwell ,
Linkedin ,
Single Institution Study ,
American Cancer Society ,
Stock Exchange Of Hong Kong ,
Nasdaq ,
China National Medical Products Administration ,
Exchange Commission ,
European Lung Cancer Congress On ,
European Lung Cancer Congress ,
National Reimbursement Drug List ,
World Health Organization ,
Astrazeneca ,
China Limited ,
International Agency For Research On Cancer ,
New Drug Application ,
Lung Cancer ,
Securities Litigation Reform Act ,
Stock Exchange ,
Hong Kong Limited ,
International Agency ,
Accessed November ,
Clinical Oncology Provisional Opinion ,
Epidermal Growth Factor Receptor ,
Mutation Testing ,
Kinase Inhibitor ,
Histological Samples ,
Small Cell Lung Cancer ,
Systematic Review ,
Intj Clin Exp ,
Mutated Advanced Non Small Cell Lung ,
Positive Lung ,
Clinical Oncology ,
Region ,